At a glance
ClinicalIndex Comparison RecordN/ACompleted· 168 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Observational, Non-interventional, Study of Patients With Hereditary Angioedema in the United States and Canada (EMPOWER Study)
In Brief
An observational study for Hereditary Angioedema (HAE). Completed, enrolled 168 participants across 29 sites in 3 countries.
Detailed Summary
The main aim of this study is to compare the HAE attack rate before and after lanadelumab treatment was started in persons with Hereditary Angioedeme Type I or II. Data from participants will be collected for at least 24 months. Participants will report information in a smartphone application at study start and then every 3 months until the study ends; data will also be collected by the study doctor during routine clinic visits.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHereditary Angioedema (HAE)
CountriesCanada, Puerto Rico, United States
CollaboratorsTakeda Development Center Americas, Inc.
Timeline
N/ACompletedFinished
20192020202120222023202420252026
First PostedFeb 2019
Enrollment StartMar 2019
Primary CompletionOct 2022
TodayJul 2026
First PostedFeb 19, 2019
Enrollment StartMar 30, 2019
Primary CompletionOct 22, 2022
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 7.4 years ago